Rare atrial defect and interatrial communication Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

1 event

Apr 2022

Cuvrior: FDA approved

Treatment of adult patients with stable Wilson®s disease who are de-coppered and tolerant to penicillamine

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Cuvrior

Orphalan

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Cuvrior

(trientine tetrahydrochloride)Orphan drug

Orphalan

12.1 Mechanism of Action Trientine, a copper chelator, eliminates absorbed copper from the body by forming a stable complex that is then eliminated th...

Approved Apr 2022FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Rare atrial defect and interatrial communication.
Search all trials →

Search clinical trials for Rare atrial defect and interatrial communication →

Recent News & Research

No recent news articles indexed yet for Rare atrial defect and interatrial communication.
Search PubMed for Rare atrial defect and interatrial communication →

Browse all Rare atrial defect and interatrial communication news →

Specialist Network

No specialists currently listed for Rare atrial defect and interatrial communication.

View all Rare atrial defect and interatrial communication specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰